Want to see SCYX full AI Analyst Report?
Top Page
SCYNEXIS
(NASDAQ:SCYX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.50
▲(47.45% Upside)
Action:Reiterated
Date:08/01/26
The score is primarily weighed down by weak financial performance—large recent losses and ongoing cash burn—despite a relatively low-leverage balance sheet. Technicals show improving near-term momentum but a still-negative longer-term trend, while valuation is constrained by loss-making results and no dividend. Corporate actions add potential share-supply overhang, modestly pressuring the outlook.
Positive Factors
Approved Lead Product
Regulatory approval of ibrexafungerp (BREXAFEMME) establishes a commercial foothold and de-risks part of development pipeline. An approved asset provides durable revenue potential via product sales and partner royalties while enabling further label expansion and lifecycle planning.
Negative Factors
Negative Cash Flow
Sustained negative operating and free cash flow means the company requires external financing or partner funding to sustain operations and trials. Persistent cash burn increases dilution risk and can constrain strategic options, affecting long-term program continuity and investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Approved Lead Product
Regulatory approval of ibrexafungerp (BREXAFEMME) establishes a commercial foothold and de-risks part of development pipeline. An approved asset provides durable revenue potential via product sales and partner royalties while enabling further label expansion and lifecycle planning.
Read all positive factors
SCYNEXIS (SCYX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.06M
Dividend YieldN/A
Average Volume (3M)612.75K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth673.54%
EPS Growth23.14%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-3.58
Shares Outstanding9,930,329
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside369.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.25
Revenue Forecast (FY)$1.17M
SCYNEXIS Business Overview & Revenue Model
Company Description
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive ...
How the Company Makes Money
SCYNEXIS generates revenue primarily through partnering and commercialization arrangements rather than running a large standalone sales infrastructure. Key revenue streams include: (1) collaboration/licensing revenue such as upfront payments, mile...
SCYNEXIS Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.34M | 20.60M | 3.75M | 140.14M | 5.09M | 13.16M |
| Gross Profit | 20.34M | 20.60M | 3.75M | 124.52M | 4.46M | 12.85M |
| EBITDA | -24.52M | -8.12M | -18.58M | 70.89M | -59.91M | -32.91M |
| Net Income | -24.52M | -8.61M | -21.29M | 67.04M | -62.81M | -32.87M |
Balance Sheet | ||||||
| Total Assets | 77.63M | 59.03M | 90.64M | 128.41M | 87.81M | 119.84M |
| Cash, Cash Equivalents and Short-Term Investments | 59.26M | 21.26M | 59.30M | 74.36M | 73.50M | 104.48M |
| Total Debt | 2.06M | 2.17M | 16.27M | 15.08M | 48.60M | 43.63M |
| Total Liabilities | 36.32M | 9.65M | 35.57M | 55.45M | 84.58M | 78.58M |
| Stockholders Equity | 41.31M | 49.38M | 55.08M | 72.96M | 3.23M | 41.26M |
Cash Flow | ||||||
| Free Cash Flow | -5.92M | -5.28M | -24.01M | 60.16M | -79.89M | -55.73M |
| Operating Cash Flow | -5.92M | -5.28M | -24.01M | 60.16M | -79.88M | -54.56M |
| Investing Cash Flow | 11.34M | 24.31M | 6.15M | -34.88M | -27.39M | -1.17M |
| Financing Cash Flow | 23.95M | -14.17M | -139.00K | -36.72M | 48.60M | 67.12M |
SCYNEXIS Technical Analysis
Neutral
3.73
Price Trends
4.42
Positive
5.84
Negative
5.71
Negative
Market Momentum
0.14
Negative
62.46
Neutral
85.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Neutral. The current price of 3.73 is below the 20-day moving average (MA) of 4.37, below the 50-day MA of 4.42, and below the 200-day MA of 5.71, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 62.46 is Neutral, neither overbought nor oversold. The STOCH value of 85.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SCYX.
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SCYNEXIS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $100.09M | -13.51 | -28.75% | ― | 2.08% | -106.57% | |
54 Neutral | $28.38M | -4.84 | -15.41% | ― | -30.75% | -1059.59% | |
54 Neutral | $23.50M | 131.82 | 0.66% | ― | 82.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $48.06M | -1.35 | -57.16% | ― | 673.54% | 23.14% | |
47 Neutral | $23.94M | -0.52 | -148.91% | ― | -18.24% | -2264.65% | |
41 Neutral | $1.04M | -1,062.50 | -3.03% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
SCYX
SCYNEXIS
5.20
-1.80
-25.71%
RMTI
Rockwell Med
7.16
-2.64
-26.94%
TXMD
TherapeuticsMD
2.09
0.99
90.00%
AYTU
Aytu BioScience
2.33
-0.04
-1.69%
CPIX
Cumberland Pharmaceuticals
7.68
5.14
202.01%
IMCC
IM Cannabis Corp
0.12
-2.44
-95.20%
SCYNEXIS Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
Positive
Jun 26, 2026
At its Annual Meeting of Stockholders held on June 25, 2026, SCYNEXIS, Inc. shareholders re-elected six directors to serve until the 2027 meeting and ratified Deloitte Touche LLP as the company’s independent auditor for the 2026 fiscal year...
Shareholder MeetingsStock Split
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split
Neutral
May 22, 2026
On May 19, 2026, SCYNEXIS stockholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split in a range between 1-for-5 and 1-for-10 and a reduction in authorized shares, with 44,826,378 votes ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.